University of Zurich registers Phase 2 safusidenib trial in IDH1-mutant grade 3 gliomaSep 21Trial updateNuvation Bio Inc.safusidenib
Nuvation Bio posts Q2 2026 results, expands safusidenib program, reports IBTROZI uptake dataAug 6Quarterly updateNuvation Bio Inc.safusidenib
Nuvation Bio registers two new trials for IDH1-mutant glioma drug safusidenibJul 17Weekly roundup, 2 itemsNuvation Bio Inc.safusidenib
Nuvation Bio's underwriters fully exercise greenshoe on convertible notes offeringJul 6FinancingNuvation Bio Inc.
Sign inSign in